Maintenance Notice (10:30 PM August 23 - 3:30 AM August 24, 2025 UTC): This website is scheduled to be unavailable due to maintenance. We appreciate your patience and understanding.
Product Document Searching Made Easy by 2D Code! | TCI Life Science News August 2025 | [Product Highlights] Puberulic Acid: A Compound with... | Various analytical charts can be searched on each product detail page and Product Document Search (The kinds of analytical charts differ by product)
Maximum quantity allowed is 999
请选择数量
CAS RN: 366789-02-8 | 产品编码: R0269
Rivaroxaban
×
![]()
×
| 产品编码 | R0269 |
纯度/分析方法 
|
>98.0%(T)(HPLC) |
| 分子式/分子量 | C__1__9H__1__8ClN__3O__5S = 435.88 |
| 外观与形状（20°C） | 固体 |
| 储存温度
|
冷藏 (0-10°C) |
| 储存在惰性气体下 | 存放于惰性气体之中 |
| 应避免的情况 | 空气,加热 |
| CAS RN | 366789-02-8 |
| Reaxys-RN | 10206739 |
| MDL编号 | MFCD11974010 |
技术规格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Volumetric Analysis) | min. 98.0 % |
| Melting point | 230.0 to 234.0 °C |
| Specific rotation | -40.0 to -44.0 deg(C=1, DMSO) |
| NMR | confirm to structure |
物性（参考值）
| 熔点 | 232 °C |
| 水溶性 | 不溶 |
| 溶解性（可溶于） | 二甲基甲酰胺 |
GHS
| 象形图 |
|
| 信号词 | Warning |
| 危险性说明 | H361 : Suspected of damaging fertility or the unborn child. H371 : May cause damage to organs. |
| 防范说明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P311 : IF exposed or concerned: Call a POISON CENTER/doctor. P405 : Store locked up. |
相关法规
运输信息
| HS编码* | 2934.99-000 |
应用
Rivaroxaban: A Selective Inhibitor of the Serine Protease, Activated Anticoagulant Factor X (FXa)
Rivaroxaban (BAY 59-7939) is a selective inhibitor of the serine protease, activated anticoagulant factor X (FXa) that catalyzes the conversion of prothrombin to thrombin. Rivaroxaban works by selectively and reversibly blocking the activity of clotting FXa, thereby preventing the formation of blood clots. Thus, inhibition of FXa may block this burst of thrombin generation, thereby reducing thrombin-mediated activation of coagulation and platelets. In another words, rivaroxaban does not directly affect platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. (The product is for research purpose only.)
References
- In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 -an oral, direct factor Xa inhibitor
- Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases (a review)
- The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
- Determination of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。